Two medicines, side by side
Indapamide vs hydrochlorothiazide
Indapamide and hydrochlorothiazide are both labeled for high blood pressure, heart failure and edema (fluid retention). Drugs@FDA records approvals of indapamide since 1983 and of hydrochlorothiazide since 1959. Pharmacies paid $0.109 per indapamide 1.25 mg tablet and $0.0115 per hydrochlorothiazide 25 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. Hydrochlorothiazide's other strengths are brand-only: $4.46 per mL (Inzirqo 10 mg/mL oral suspension). In FDA's classes, indapamide is a thiazide-like diuretic and hydrochlorothiazide a thiazide diuretic.
Check it at the source: the indapamide FDA label on DailyMed (effective October 1, 2022); the hydrochlorothiazide FDA label on DailyMed (effective June 12, 2026).
Highlights of the indapamide record
Indapamide (Lozol) · label of October 1, 2022
Used for
From the label: indicationsIndapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see PRECAUTIONS ). […]
On the market
- Earliest approval on file
- July 6, 1983
- Generic labelers
- 8 labelers
- Pharmacy cost
- $0.109 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the hydrochlorothiazide record
Hydrochlorothiazide (Inzirqo) · label of June 12, 2026
Used for
From the label: indicationsHydrochlorothiazide tablets USP are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets USP have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. […]
On the market
- Earliest approval on file
- February 12, 1959
- Generic labelers
- 43 labelers
- Pharmacy cost
- $0.0115 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 7
Source: FDA drug labels via openFDA (Indapamide label of October 1, 2022, Hydrochlorothiazide label of June 12, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do indapamide and hydrochlorothiazide differ on the record?
In FDA's classes, indapamide is a thiazide-like diuretic and hydrochlorothiazide a thiazide diuretic.
Half-life, in each label's words: Indapamide, “The half-life of indapamide in whole blood is approximately 14 hours.”; Hydrochlorothiazide, “When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 …”
Generics: indapamide since 1995; hydrochlorothiazide since 1973 (Drugs@FDA).
| Indapamide | Hydrochlorothiazide | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure, Edema (fluid retention) | Heart failure, High blood pressure, Edema (fluid retention) |
| Pharmacologic class | Thiazide-like Diuretic | Thiazide Diuretic |
| How it works (label) | n/a | n/a |
| Half-life (label) | The half-life of indapamide in whole blood is approximately 14 hours. | When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours. |
| Earliest approval on file (Drugs@FDA) | July 6, 1983 | February 12, 1959 |
| First generic approved | July 27, 1995 | January 12, 1973 |
| Generic labelers (NDC) | 8 labelers | 43 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.109 per tablet (Indapamide 1.25 mg tablet) | $0.0115 per tablet (Hydrochlorothiazide 25 mg tablet) |
| 12-month price change | +9% | -7% |
| Boxed warning | No | No |
| Shortage now | No current entry | A presentation being discontinued |
| Recalls recorded | 0 | 7 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 17,817 | 144,413 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to indapamide
- every medicine labeled for the same conditions